MorphoSys AG buy Nordlicht1337
Summary
This prediction ended on 27.10.14 with a price of €73.60. The prediction had a final performance of 22.36%. Nordlicht1337 has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 0.300% | 0.300% | 232.093% | -0.342% |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
Comments by Nordlicht1337 for this prediction
In the thread Morphosys AG diskutieren
Biotech
Morphosys ist unter den Biotechs einer der stärksten Titel und könnte, nach den momentanen Verunsicherungen im Gesamtmarkt, möglicherweise danach zu den Outperformern gehören. Die Deutsche Bank hält nach einer ihrer letzten Analysen sogar eine Verdreifachung für möglich. ( http://www.deraktionaer.de/aktie/morphosys--aktie-startet-durch---kursziel-300-euro-51710.htm )